ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO941

Major Adverse Kidney Events in Multidisciplinary CKD Care Compared With Usual Outpatient Care: A Propensity Score Matched Analysis

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • Chittinandana, Palita, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Gojaseni, Pongsathorn, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Chuasuwan, Anan, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Chailimpamontree, Worawon, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Chittinandana, Anutra, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand

Chronic kidney disease (CKD) causes a public health problem worldwide. Multidisciplinary CKD care (MDC) has been recommended in clinical practice guideline to delay disease progression and minimize complications. However, effectiveness of MDC on major adverse kidney events (MAKE) in CKD patients is still inconclusive.


We conducted a cohort study in patients with CKD stage G3b and 4 who were followed up at Bhumibol Adulyadej Hospital since 2014 to 2020. Propensity score matching by age, sex, CKD staging, diabetes, blood pressure and rate of estimated glomerular filtration rate (eGFR) decline before inclusion between patients in MDC and usual outpatient care (UOC) was done. The primary outcome was MAKE, a composite of cardiovascular or renal mortality, 40% eGFR decline and initiation of long-term kidney replacement therapy.


After 1:1 propensity score matching, 822 patients were included. The mean age was 70.9 years, 64% have diabetes. During the mean follow up of 3.3 years, rate of the primary endpoint was lower in MDC group than UOC group (24.1% vs. 38.9%; hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.52 to 0.86; P=0.002). The results showed benefit of MDC over UOC in 40% eGFR declined (21.7% vs. 35.0%; HR, 0.67; 95%CI 0.52 to 0.88; P=0.004), all-cause mortality (8.5% vs. 19.5%; HR, 0.60; 95%CI 0.40 to 0.90; P=0.014), non-cardiovascular death (6.1% vs. 15.1%; HR, 0.56; 95%CI 0.35 to 0.90; P=0.015) and hospitalization per year (1.0 ± 1.5 vs. 1.6 ± 2.0; P<0.005). According to subgroup analysis, diabetic patients benefit the most from MDC.


In a tertiary care hospital, MDC showed benefits over UOC on kidney outcomes in patients with CKD stage G3b and 4. The benefit will be enhanced in diabetes group.

Figure 1. Forest plot comparing primary and secondary outcome between MDC and UOC


  • Government Support – Non-U.S.